An emerging ingredient
Pyrroloquinoline quinone, commonly abbreviated PQQ, is a compound studied for possible roles in cell signaling and mitochondrial biology. It has generated interest in laboratory and animal research, and some small human studies have examined outcomes related to exercise or other markers.
The manufacturer describes PQQ in cautious terms on its public product page: animal research suggests potential effects on mitochondria in animals, and at least one human study in men engaged in aerobic exercise examined certain proteins. This description itself points to a limited evidence base, not a proven result for all consumers.
What the label says
The September 2026 label transcription lists 5 mg of pyrroloquinoline quinone disodium salt per two-capsule serving. A milligram amount tells you how much of an ingredient is listed, but it does not tell you whether the amount produces a meaningful health outcome.
What stronger evidence would look like
For a product-specific claim, the most relevant evidence would test the complete marketed formula in an appropriately designed human trial. The study should identify the serving, duration, participants, comparison group, and prespecified outcomes. Ideally, independent researchers would replicate the findings.
Until then, the fair way to discuss PQQ is as an ingredient of scientific interest with early research—not as a proven way to create new mitochondria in a person or reverse age-related energy loss.